Low gene expression of SPRY2 in breast cancer tissues correlated with increased pathological grade as well as high expression of HER2; In trastuzumab treated patients, low SPRY2 expression was associated with an increased risk of death.26, 27. Here, ERBB2 is linked to breast cancer.